Novartis Files For Approval Of Rasilez In Japan
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharma of Japan has applied for approval of the high blood pressure drug Rasilez (aliskiren). Aliskiren is the first in a new class of medicine that works by inhibiting renin (an enzyme secreted by the kidney). Aliskirenhas been approved by the U.S. FDA and is sold under the name Tektuna in the U.S. and as Rasilez in Europe. (Click here for more - Japanese language